Atypical Hemolytic Uremic Syndrome (aHUS) is defined by thrombocytopenia, hemolytic anemia, and acute renal failure. FEIBA is a concentrate of inactivated and activated coagulation factors that has been classically used to establish hemostasis in those with hemophilia or acquired factor inhibitors. However, recently it has seen used off-label as an anticoagulant reversal therapy amongst the general population.
Herein, we report for the first time aHUS attributed to the administration of a single large dose of FEIBA for anticoagulation reversal treated with hemodialysis and four weekly doses of eculizumab to quell disease and achieve dialysis independence.
Tsai, Hsin Hsiang C.
"Atypical Hemolytic Uremic Syndrome: An Unusual Complication of Activated Prothrombin Complex Concentrate,"
Loma Linda University Student Journal: Vol. 4
, Article 8.
Available at: https://scholarsrepository.llu.edu/llu-student-journal/vol4/iss1/8